Physician
Infectious Disease
Dr. David R. Andes, MD
David Andes works in the field of Infectious Disease. He graduated from University of Missouri-Columbia School of Medicine. He over the years received 3 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Elected Member". David R. Andes, MD is a published physician as well. He has 76 publications published. The latest was: Targeting fibronectin to disrupt in vivo Candida biofilms.
Publications
- Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.
- Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
- Targeting fibronectin to disrupt in vivo Candida biofilms.
- Development of New Strategies for Echinocandins: Progress in Translational Research.
- Extended Interval Micafungin Using Humanized PK/PD in Mice.
- In vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709 and its Active Metabolite TXA-707, in the Murine Neutropenic Thigh Infection Model.
- An Expanded Regulatory Network Temporally Controls Candida albicans Biofilm Formation.
- Community participation in biofilm matrix assembly and function.
- Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), using an In Vivo Murine Invasive Candidiasis Model.
- In vivo Pharmacokinetics and Pharmacodynamics of the Lantibiotic, NAI-107, in the Neutropenic Murine Thigh Infection Model.
- Antifungal Pharmacokinetics and Pharmacodynamics.
- Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the Ceftolozane In Vivo Pharmacokinetic/Pharmacodynamic Target.
- Rat Indwelling Urinary Catheter Model of Candida albicans Biofilm Infection.
- Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models: Iden...
- Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET).
- Failure of Clindamycin to Eradicate Infection with Beta-Hemolytic Streptococci Inducibly Resistant to Clindamycin in an Animal Model and in Human Infections.
- Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates...
- Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.
- Mechanisms of Candida biofilm drug resistance.
- Isavuconazole Pharmacodynamic Target Determination for Candida species in an In vivo Murine Disseminated Candidiasis Model.
- Insights into fungal pathogenesis from the iatrogenic epidemic of Exserohilum rostratum fungal meningitis.
- Histoplasmosis After Solid Organ Transplantation.
- Synthesis and antibacterial activity of doxycycline neoglycosides.
- Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization.
- Impact of in vivo Triazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy against Cyp51 Mutant Isolates.
- Role of matrix ?-1,3 glucan in antifungal resistance of non-albicans Candida biofilms.
- Antifungal therapy: current concepts and evidence-based management.
- Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 105 and 107 CFU Injected ...
- Reply to Oude Lashof.
- Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis.
- In-Vivo Activity of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including Strains with Extende...
- Posaconazole Pharmacodynamic Target Determination against Wild-type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an in vivo Model of Invasive Pulmonary Asperg...
- Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
- Natural Product Disaccharide Engineering through Tandem Glycosyltransferase Catalysis Reversibility and Neoglycosylation.
- Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In vivo Pharmacodynamic Evaluation Against C. glabrata with and without Fks Mutations.
- Addition of ceftaroline to daptomycin after the emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves anti-bacterial activity.
- A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance.
- Reply to Anaissie and Nucci and to Cisneros et al.
- Antifungal Therapeutic Drug Monitoring Progress: Getting It Right the First Time.
- Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials.
- Antifungal PK/PD Considerations in Fungal Pulmonary Infections.
- Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.
- In vitro susceptibility of Aspergillus to echinocandins: Isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.
- Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation.
- A comparison of in vitro susceptibility of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: TRANSNET 2001-2006.
- Comparative analysis of Candida biofilm quantitation assays.
- Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.
- Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay.
- Conserved and Divergent Roles of Bcr1 and CFEM Proteins in Candida parapsilosis and Candida albicans.
- Development and validation of an in vivo Candida albicans biofilm denture model.
- Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene.
- Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan.
- Factors associated with mortality in transplant patients with invasive aspergillosis.
- Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Su...
- Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).
- Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.
- Time course global gene expression analysis of an in vivo Candida biofilm.
- Biofilm matrix regulation by Candida albicans Zap1.
- Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
- Association of fluconazole pharmacodynamics with mortality in patients with candidemia.
- Reduced biocide susceptibility in Candida albicans biofilms.
- Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphyl...
- Function of Candida albicans adhesin Hwp1 in biofilm formation.
- Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo.
- Inhibition of mutation and combating the evolution of antibiotic resistance.
- Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
- Regulation of iron transport in Streptococcus pneumoniae by RitR, an orphan response regulator.
- Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vi...
- Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.
- Fungal Biofilms, Drug Resistance, and Recurrent Infection.
- Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in Aspergillus fumigatus.
- Regulatory Role of Glycerol in Candida albicans Biofilm Formation.
- A Histone Deacetylase Complex Mediates Biofilm Dispersal and Drug Resistance in Candida albicans.
- Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registr...
Schools
University Of Missouri Columbia Campus
University Of Wi Hospital and Cli
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
University of Wisconsin -
University of Missouri-Columbia School of Medicine
Hospital
-
William S. Middleton Memorial Veterans Hospital
Drug Facts
| NPI NUMBER | 1154398857 | |
| NPPES Provider LastName | ANDES | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 53792 | |
| NPPES Provider State | WI | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 269.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1154398857 |
| Last Name Of The Provider | ANDES |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Frank P. Polyak, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard M. Reich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William A. Craig, MD |
|
|
Dr. Barry C. Fox, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bennett S. Vogelman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander J. Lepak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeniel E. Nett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan P. Westergaard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Crnich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert T. Striker, MD
This Doctor is OpenDoctor Recommended.
|